April 30, 2008--Incyte Corporation (Nasdaq:INCY) reported first quarter 2008 financial results and reviewed recent clinical accomplishments in multiple programs......
11beta-HSD1 Inhibitor Program
INCB13739: Type 2 Diabetes
- Confirmed that results from the 28-day Phase IIa trial will be presented by the principal investigator at the American Diabetes Association meeting on June 9, 2008
- Finalized the protocol for the three-month Phase IIb trial which is scheduled to initiate in May 2008
INCB20817: Type 2 Diabetes
- Initiated Phase I trials
HM74a Agonist Program
INCB19602: Type 2 Diabetes
- Completed Phase I trials in which the compound was well tolerated, lowered free fatty acids without rebound and did not produce the flushing seen with niacin and its derivatives
- Results from the Phase I trials support the initiation of a 28-day Phase IIa trial in type 2 diabetics that is expected to provide top-line proof-of-concept data later this year or early next year...
